Close this search box.

Ardena’s success leads to major €35 million investment for expansion in Belgium, Sweden and The Netherlands

Gent, Belgium/July 2021: Ardena, a specialist pharmaceutical Contract Development and Manufacturing Organisation (CDMO), in partnership with GHO Capital, announced today a major €35 million investment for expansion across its European operations.

The investment will future proof offerings for the biopharma and emerging biotechnology sectors and positions Ardena to become a leading global CDMO, offering end-to-end solutions spanning the full pharma development lifecycle.

Ardena will significantly expand drug product services in Belgium and aseptic fill and finish capabilities for the development and clinical production of small molecule, injectable formulations. Capacity for large molecule biologics will expand to include Peptides, Oligonucleotides (DNA, recombinant RNA, synthetic RNA, RNA vaccines) and Proteins.

This will provide clients with a full-service solution from formulation development, analytical method development and validation, demo batch production, stability studies, GMP batch production, QC testing, labelling and randomization, QP release, storage and shipping through to regulatory support.

The Swedish facility will undergo expansion to support the commercialization of COVID-19 vaccines and further growth of the API business. This will enable more preparative chromatography and HPLC and further expansion of advanced and specialized filtration technology along with lyophilization capacity for bulk quantities.

The investment program will see major improvements in the Netherlands facility, continuing the growth of the API and Nanomedicine activities. This will include the expansion of cleanroom space (Grade D and C), chemical manufacturing capacity, warehouse space, adding chemistry and analytical labs and investing in new technologies to support Ardena’s leadership in Nanotechnology.

“The significant investment in our expansion is a result of our continued outperformance of the market,” said Harry Christiaens, Ardena CEO. “Our focus on the exciting world of early phase development at an international level has proven to be highly successful. We have a great deal of scientific expertise and will continue to invest in the people and resources we need to deliver for our clients.”

“This an exciting time to be at Ardena,” explained Gerjan Kemperman, Ardena COO. “We have the international experience and network to expertly manage multiple projects, whatever the demands of the market or the technologies required.”

Pivot Park Captains' Dinner

10 years ago, Pivot Park opened its doors to the world. Thanks to your commitment, support and confidence, we have been able to grow it into the successful and innovative biopharmaceutical campus it is today.

Now it’s time to celebrate!

We are therefore delighted to invite you – along with all your fellow CEOs at Pivot Park – to a special night out featuring inspiring art, a wonderful dinner and lots of opportunities to network and exchange ideas.

Erwin Wurm | Am I a House?

For the first time, the artist shows a cross-section of his work, from Narrow Furniture to One Minute Sculptures, within the walls of a historic building. Villa Constance, a former home that today houses Museum Jan Cunen, is not only a location but also part of the conversation. Because what exactly is a house?


The development of medicines in Oss began one hundred years ago. It was then that the foundations were laid for what would become a flourishing pharmaceutical sector in the Netherlands, leading to groundbreaking discoveries such as insulin and the anti-conception pill.

Today, the entire chain is still represented in Oss, from early-stage research to the commercial scale production of medicines. Working in Oss, we focus on the health of people all over the world. Employees at dozens of companies large and small put their heart and soul into new medicines, products and services that will improve lives worldwide. Together, our strength lies in our combination of broad knowledge about the development of medicines and a thorough understanding of the requirements of high-quality production.

This shared past and common values stimulate strong bonds among everyone who works in pharmaceuticals in Oss. We build on qualities, expertise and networks that go back decades. And with a wide variety of pharmaceutical companies, suppliers and scientific institutions all located nearby, we offer an attractive business climate and an excellent basis for international collaboration.

We are proud to work together to create a better and healthier future for all, a collaboration that in turn fuels growing employment: today, most pharmaceutical jobs in the Netherlands are in Oss. Here we connect talent and companies and stimulate entrepreneurship, while our expert employees are our most important asset. Their drive ensures that Oss has an influence on health all over the world.

Pharma in Oss offers endless opportunities to startups and talent in a city and region that is a joy to live and work in. We are committed to collaboration and sustainable and successful entrepreneurship. Oss’s pharmaceutical companies are intrinsically competitive while also being committed to quality and safety. This, plus their focus on new health solutions and contemporary technology, makes us a leader in our pursuit of a better life for people worldwide.